Rakovina Therapeutics Inc
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series … Read more
Rakovina Therapeutics Inc (RKV) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.548x
Based on the latest financial reports, Rakovina Therapeutics Inc (RKV) has a cash flow conversion efficiency ratio of -0.548x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-1.04 Million) by net assets (CA$1.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rakovina Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Rakovina Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Rakovina Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rakovina Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FUJIKURA - Dusseldorf Stock Exchang
DU:FJK
|
N/A |
|
2cureX AB
ST:2CUREX
|
3.288x |
|
Podravka Prehrambena Industrija d.d.
ZSE:PODR
|
N/A |
|
YouneeqAI Technical Services Inc.
PINK:YQAI
|
N/A |
|
PRIMEENERGY
BE:PEJ
|
0.049x |
|
Omniq Corp
OTCQB:OMQS
|
0.049x |
|
Odessa Capital Ltd.
V:ALFA-P
|
N/A |
|
Ocean Biomedical Inc.
NASDAQ:OCEA
|
0.026x |
Annual Cash Flow Conversion Efficiency for Rakovina Therapeutics Inc (2021–2024)
The table below shows the annual cash flow conversion efficiency of Rakovina Therapeutics Inc from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$4.30 Million | CA$-3.86 Million | -0.897x | -76.29% |
| 2023-12-31 | CA$3.66 Million | CA$-1.86 Million | -0.509x | -59.59% |
| 2022-12-31 | CA$6.01 Million | CA$-1.92 Million | -0.319x | -17.99% |
| 2021-12-31 | CA$8.54 Million | CA$-2.31 Million | -0.270x | -- |